SCHEMBL30294548

SCHEMBL30294548

Cc1cc(F)ccc1Nc1cc(Cl)ccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLCN2 P51788 1/20 0.57
GRIK1 P39086 6/20 0.54
MAPK13 O15264 1/20 0.50
MAPK12 P53778 1/20 0.50
MAPK11 Q15759 1/20 0.50
MAPK14 Q16539 1/20 0.50
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
USP2 O75604 1/20 0.49
PABPC1 P11940 1/20 0.49
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 4/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 1/20 0.48
HSD17B10 Q99714 1/20 0.46
TRPM4 Q8TD43 1/20 0.45
GAA P10253 1/20 0.45
KCNH2 Q12809 1/20 0.45
RAB9A P51151 1/20 0.45
AKR1C3 P42330 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852841 1.00 CLCN2 (0.57) CLCN2GRIK1MAPK13MAPK12MAPK11
SCHEMBL22852993 0.90 KDM4E (0.54) CLCN2GRIK1MAPK13MAPK12MAPK11
SCHEMBL30294397 0.90 KDM4E (0.54) CLCN2GRIK1MAPK13MAPK12MAPK11
SCHEMBL30294563 0.83 ALDH1A1 (0.52) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL22852829 0.83 ALDH1A1 (0.52) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL5680871 0.83 IDO1 (0.61) GRIK1KMT2AMEN1USP2PABPC1
SCHEMBL22853397 0.83 MAPT (0.49) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL30294784 0.83 MAPT (0.49) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL22853082 0.82 CLCN2 (0.53) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL30294647 0.82 CLCN2 (0.53) CLCN2MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B CLCN2 192/4885GRIK1 181/4885MAPK13 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.